Last reviewed · How we verify
DE-117B Eye Drops
DE-117B is a selective rho kinase (ROCK) inhibitor that reduces intraocular pressure by improving aqueous humor outflow through the trabecular meshwork and Schlemm's canal.
DE-117B is a selective rho kinase (ROCK) inhibitor that reduces intraocular pressure by improving aqueous humor outflow through the trabecular meshwork and Schlemm's canal. Used for Glaucoma or ocular hypertension.
At a glance
| Generic name | DE-117B Eye Drops |
|---|---|
| Sponsor | Santen Pharmaceutical Co., Ltd. |
| Drug class | Rho kinase (ROCK) inhibitor |
| Target | ROCK1/ROCK2 |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
ROCK inhibitors modulate the cytoskeleton and cell contractility in ocular tissues, particularly enhancing conventional outflow facility in the eye's drainage system. By inhibiting ROCK signaling, DE-117B increases the ease with which fluid drains from the anterior chamber, thereby lowering intraocular pressure. This mechanism differs from prostaglandin analogs and beta-blockers, offering a novel approach to glaucoma management.
Approved indications
- Glaucoma or ocular hypertension
Common side effects
- Conjunctival hyperemia
- Eye irritation
- Instillation site discomfort
Key clinical trials
- A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |